Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2022 Jan 19

PMID 35045265

Authors

Yoshitsugu Ohata

Mitsunori Tomonaga

Yasuo Watanabe

Keiko Tomura

Koji Kimura

Tatsuo Akaki

Kaoru Adachi

Eiichi N Kodama

Yuji Matsuzaki

Hironori Hayashi

Affiliations

Soon will be listed here.

Abstract

HIV-1 integrase (IN) is an essential enzyme for viral replication. Non-catalytic site integrase inhibitors (NCINIs) are allosteric HIV-1 IN inhibitors and a potential new class of antiretrovirals. In this report, we identified a novel NCINI, JTP-0157602, with an original scaffold. JTP-0157602 exhibited potent antiviral activity against HIV-1 and showed a serum-shifted 90% effective concentration (EC) of 138 nM, which is comparable to those of the FDA-approved IN strand transfer inhibitors (INSTIs). This compound was fully potent against a wide range of recombinant viruses with IN polymorphisms, including amino acids 124/125, a hot spot of IN polymorphisms. In addition, JTP-0157602 retained potent antiviral activity against a broad panel of recombinant viruses with INSTI-related resistance mutations, including multiple substitutions that emerged in clinical studies of INSTIs. Resistance selection experiments of JTP-0157602 led to the emergence of A128T and T174I mutations, which are located at the lens epithelium-derived growth factor/p75 binding pocket of IN. JTP-0157602 inhibited HIV-1 replication mainly during the late phase of the replication cycle, and HIV-1 virions produced by reactivation from HIV-1 latently infected Jurkat cells in the presence of JTP-0157602 were noninfectious. These results suggest that JTP-0157602 and analog compounds can be used to treat HIV-1 infectious diseases. Non-catalytic site integrase inhibitors (NCINIs) are allosteric HIV-1 integrase (IN) inhibitors that bind to the lens epithelium-derived growth factor (LEDGF)/p75 binding pocket of IN. NCINIs are expected to be a new class of anti-HIV-1 agents. In this study, we present a novel NCINI, JTP-0157602, which has potent activity against a broad range of HIV-1 strains with IN polymorphisms. Furthermore, JTP-0157602 shows strong antiviral activity against IN strand transfer inhibitor-resistant mutations, suggesting that JTP-0157602 and its analogs are potential agents for treating HIV-1 infections. Structural modeling indicated that JTP-0157602 binds to the LEDGF/p75 binding pocket of IN, and the results of resistance induction revealed the JTP-0157602 resistance mechanism of HIV-1. These data shed light on developing novel NCINIs that exhibit potent activity against HIV-1 with broad IN polymorphisms and multidrug-resistant HIV-1 variants.

Citing Articles

Quinolin-4-ones: Methods of Synthesis and Application in Medicine.

Gach-Janczak K, Piekielna-Ciesielska J, Waskiewicz J, Krakowiak K, Wtorek K, Janecka A Molecules. 2025; 30(1.

PMID: 39795219 PMC: 11721932. DOI: 10.3390/molecules30010163.

HIV-1 Integrase Inhibition Activity by Spiroketals Derived from , an Endemic Plant of Sardinia (Italy) and Corsica (France).

Sanna C, DAbrosca B, Fiorentino A, Giammarino F, Vicenti I, Corona A Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631033 PMC: 10457970. DOI: 10.3390/ph16081118.

Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase.

Bonnard D, Le Rouzic E, Singer M, Yu Z, Le Strat F, Batisse C Antimicrob Agents Chemother. 2023; 67(7):e0046223.

PMID: 37310224 PMC: 10353390. DOI: 10.1128/aac.00462-23.

The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function.

Singer M, Dinh T, Levintov L, Annamalai A, Rey J, Briganti L mBio. 2023; 14(1):e0356022.

PMID: 36744954 PMC: 9973045. DOI: 10.1128/mbio.03560-22.

Allosteric Integrase Inhibitor Influences on HIV-1 Integration and Roles of LEDGF/p75 and HDGFL2 Host Factors.

Singh P, Li W, Bedwell G, Fadel H, Poeschla E, Engelman A Viruses. 2022; 14(9).

PMID: 36146690 PMC: 9502684. DOI: 10.3390/v14091883.

References

Christ F, Shaw S, Demeulemeester J, Desimmie B, Marchand A, Butler S . Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother. 2012; 56(8):4365-74. PMC: 3421592. DOI: 10.1128/AAC.00717-12. View

Japour A, Mayers D, Johnson V, Kuritzkes D, Beckett L, Arduino J . Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance.... Antimicrob Agents Chemother. 1993; 37(5):1095-101. PMC: 187907. DOI: 10.1128/AAC.37.5.1095. View

Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A . Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284-91. PMC: 253077. DOI: 10.1128/JVI.59.2.284-291.1986. View

Le Rouzic E, Bonnard D, Chasset S, Bruneau J, Chevreuil F, Le Strat F . Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. Retrovirology. 2013; 10:144. PMC: 4222603. DOI: 10.1186/1742-4690-10-144. View

Hombrouck A, De Rijck J, Hendrix J, Vandekerckhove L, Voet A, De Maeyer M . Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog. 2007; 3(3):e47. PMC: 1839165. DOI: 10.1371/journal.ppat.0030047. View

Sharma A, Slaughter A, Jena N, Feng L, Kessl J, Fadel H . A new class of multimerization selective inhibitors of HIV-1 integrase. PLoS Pathog. 2014; 10(5):e1004171. PMC: 4038613. DOI: 10.1371/journal.ppat.1004171. View

Garvey E, Johns B, Gartland M, Foster S, Miller W, Ferris R . The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2007; 52(3):901-8. PMC: 2258521. DOI: 10.1128/AAC.01218-07. View

Hazuda D, Hastings J, Wolfe A, Emini E . A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res. 1994; 22(6):1121-2. PMC: 307941. DOI: 10.1093/nar/22.6.1121. View

Hayashi H, Takamune N, Nirasawa T, Aoki M, Morishita Y, Das D . Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. Proc Natl Acad Sci U S A. 2014; 111(33):12234-9. PMC: 4142999. DOI: 10.1073/pnas.1400027111. View

10.

Cocohoba J, Dong B . Raltegravir: the first HIV integrase inhibitor. Clin Ther. 2008; 30(10):1747-65. DOI: 10.1016/j.clinthera.2008.10.012. View

11.

Feng L, Dharmarajan V, Serrao E, Hoyte A, Larue R, Slaughter A . The Competitive Interplay between Allosteric HIV-1 Integrase Inhibitor BI/D and LEDGF/p75 during the Early Stage of HIV-1 Replication Adversely Affects Inhibitor Potency. ACS Chem Biol. 2016; 11(5):1313-21. PMC: 4874862. DOI: 10.1021/acschembio.6b00167. View

12.

Unger N, Worley M, Kisgen J, Sherman E, Childs-Kean L . Elvitegravir for the treatment of HIV. Expert Opin Pharmacother. 2016; 17(17):2359-2370. DOI: 10.1080/14656566.2016.1250885. View

13.

Hoyte A, Jamin A, Koneru P, Kobe M, Larue R, Fuchs J . Resistance to pyridine-based inhibitor KF116 reveals an unexpected role of integrase in HIV-1 Gag-Pol polyprotein proteolytic processing. J Biol Chem. 2017; 292(48):19814-19825. PMC: 5712621. DOI: 10.1074/jbc.M117.816645. View

14.

Rahman S, Lu R, Vandegraaff N, Cherepanov P, Engelman A . Structure-based mutagenesis of the integrase-LEDGF/p75 interface uncouples a strict correlation between in vitro protein binding and HIV-1 fitness. Virology. 2006; 357(1):79-90. DOI: 10.1016/j.virol.2006.08.011. View

15.

Tsiang M, Jones G, Hung M, Mukund S, Han B, Liu X . Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex. J Biol Chem. 2009; 284(48):33580-99. PMC: 2785201. DOI: 10.1074/jbc.M109.040121. View

16.

Tsiang M, Jones G, Niedziela-Majka A, Kan E, Lansdon E, Huang W . New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem. 2012; 287(25):21189-203. PMC: 3375541. DOI: 10.1074/jbc.M112.347534. View

17.

Bruggemans A, Vansant G, Balakrishnan M, Mitchell M, Cai R, Christ F . GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture. Antimicrob Agents Chemother. 2021; 65(5). PMC: 8092873. DOI: 10.1128/AAC.02328-20. View

18.

Larder B, Kohli A, Kellam P, Kemp S, KRONICK M, Henfrey R . Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature. 1993; 365(6447):671-3. DOI: 10.1038/365671a0. View

19.

Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P . A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med. 2005; 11(12):1287-9. DOI: 10.1038/nm1329. View

20.

Jones G, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J . Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 2008; 53(3):1194-203. PMC: 2650545. DOI: 10.1128/AAC.00984-08. View